Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;187(6):1032-1035.
doi: 10.1111/bjd.21820. Epub 2022 Sep 1.

COVID-19 pandemic-associated chilblains: more links for SARS-CoV-2 and less evidence for high interferon type I systemic response

Affiliations

COVID-19 pandemic-associated chilblains: more links for SARS-CoV-2 and less evidence for high interferon type I systemic response

Didier Bessis et al. Br J Dermatol. 2022 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Examples of clinical manifestations of COVID‐19‐associated chilblains. Left to right: (i) typical chilblain pattern with circumscribed red macules and papules overlying the dorsal and distal phalanges of the toes; (ii) acral erythema pattern with well‐delineated symmetrical erythema and slight oedema located on the distal part of the toes; (iii) close‐up view of typical chilblains and Raynaud phenomenon of the distal phalanges of the toes; (iv) chilblains of the toes associated with BASCULE syndrome, characterized by Bier anaemic macules, cyanosis, and multiple irregular red‐orange macules (white arrows); (v) dilated capillaries and subungual splinter haemorrhages on the distal part of the nail plate. (b) Whole‐blood interferon (IFN) score and relative expression of the six interferon‐stimulated genes (ISGs) used for the IFN signature in healthy volunteers (HV; n = 24), a cohort of patients with COVID 19‐associated chilblains (CAC; n = 19), a cohort of critically ill patients with COVID‐19 in the intensive care unit (ICU; n = 72) and a cohort of nonhospitalized patients with nonsevere COVID‐19 (benign; n = 8). Relative quantification of ISGs was performed using the nCounter analysis system (NanoString Technologies, Seattle, WA, USA). (c) Plasma ISG score (IFN signature). The cutoff value for positive IFN signature was > 3·2 (lower positive = 2·3–3·2, negative < 2·3). From left to right: patients with COVID 19‐associated chilblains (n = 19); nonhospitalized patients with nonsevere COVID‐19 without CAC (n = 8); and critically ill patients with COVID‐19 in the intensive care unit (n = 72). ISGs were analysed using restricted cubic splines and are displayed as continuous variables.

References

    1. Sánchez‐García V, Hernández‐Quiles R, de‐Miguel‐Balsa E et al. Are the chilblain‐like lesions observed during the COVID‐19 pandemic due to severe acute respiratory syndrome coronavirus 2? Systematic review and meta‐analysis. J Eur Acad Dermatol Venereol 2022; 36:24–38. - PMC - PubMed
    1. Arkin LM, Moon JJ, Tran JM et al. From your nose to your toes: a review of severe acute respiratory syndrome coronavirus 2 pandemic‐associated pernio. J Invest Dermatol 2021; 141:2791–6. - PMC - PubMed
    1. Gehlhausen JR, Little AJ, Ko CJ et al. Lack of association between pandemic chilblains and SARS‐CoV‐2 infection. Proc Natl Acad Sci USA 2022; 119:e2122090119. - PMC - PubMed
    1. Rocha KO, Zanuncio VV, Freitas BAC, Lima LM. ‘COVID toes’: a meta‐analysis of case and observational studies on clinical, histopathological, and laboratory findings. Pediatr Dermatol 2021; 38:1143–9. - PMC - PubMed
    1. Toh ZQ, Anderson J, Mazarakis N et al. Comparison of seroconversion in children and adults with mild COVID‐19. JAMA Netw Open 2022; 5:e221313. - PMC - PubMed

Substances